New Products/
New Indications

FDA Approved
Oncology
Alunbrig™ (brigatinib)
Bavencio® (avelumab) - new indication
IDHIFA® (enasidenib)
Imbruvica® (ibrutinib) - new indication
Imfinzi™ (durvalumab)
Keytruda® (pembrolizumab) - new indication
Lynparza™ (olaparib) - new formulation
Opdivo® - new indication
Rituxan Hycela™ (rituximab/hyaluronidase human)
Tafinlar® (dabrafenib) & Mekinist® (trametinib) - new indication
Pharmaceuticals
Actemra® (tocilizumab) for subcutaneous injection - new indication
Ingrezza™ (valbenazine)
Radicava™ (edaravone)
Sodium phenylacetate and sodium benzoate injection


At ASD Healthcare, we continuously expand our product lines to ensure access to the products your patients need. We’re highlighting our newly added products here to make reviewing fast and easy. In addition, we're providing new product indications as they are approved by the FDA. To verify a product is appropriate for your facility to order, simply contact your sales representative. We’re always here to help.

To see the most up-to-date list of new products available from ASD Healthcare, simply check back each week!
 
Access additional
Product Resources